Pharma Industry

Having ploughed through the tough terrain of specialty drugs in the US, Indian pharma rethinks route.



In the hope of going up the value chain, generics-dependent Indian pharma companies ventured into the specialty-drugs market in the US. Barring Sun Pharma, none of the players has been able to make much headway. A few remain optimistic, while others are tweaking their strategies.

A few years ago, Indian pharmaceutical companies were gung-ho about the specialty-drugs business and believed it was the next growth lever in the US market, where their mainstay generics business had started coming under pressure. When they did enter the specialty-drugs business, it turned out to be an uncharted territory, which sprang some unpleasant surprises. High investments, long gestation periods, and challenges in gaining meaningful

  • SAVE

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise


Source link